Max Rosett - 19 Sep 2024 Form 4 Insider Report for Immunome Inc. (IMNM)

Signature
/s/ Sandra Stoneman, Attorney-in-Fact
Issuer symbol
IMNM
Transactions as of
19 Sep 2024
Net transactions value
-$186,124
Form type
4
Filing time
20 Sep 2024, 19:26:16 UTC
Previous filing
13 Aug 2024
Next filing
31 Jul 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IMNM Common Stock Options Exercise $44,100 +42,000 +212% $1.05 61,856 19 Sep 2024 Direct
transaction IMNM Common Stock Sale $230,224 -14,380 -23% $16.01 47,476 19 Sep 2024 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IMNM Stock option (right to buy) Options Exercise $0 -42,000 -31% $0.000000 91,848 19 Sep 2024 Common Stock 42,000 $1.05 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares were sold pursuant to sell to cover transactions.
F2 The weighted average sale price for the transaction report was $16.01, and the range of prices were between $15.97 and $16.10. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.
F3 The Reporting Person's Form 3 filed on October 12, 2023 contains a scrivener's error reflecting an exercise price of $1.06 instead of the correct exercise price of $1.05.
F4 25% of the shares vested on March 24, 2023, and the remaining shares shall vest in 36 monthly installments thereafter.